FLAG Therapeutics is an oncology company focused on the development of therapies based on two investigational product platforms - the anti-angiogenic, anti-tubulin platform (AA/AT), and purine synthesis inhibitors (PSI). The platforms are designed to target and destroy cancer cells through the established mechanism of actions.